U.S. President Donald Trump has issued an executive order that could potentially reclassify marijuana to a less stringent category, paving the way for expanded medical research opportunities. This move represents a significant departure from current federal drug policy and aligns more closely with the stance adopted by numerous states.
If the reclassification is approved by the Drug Enforcement Administration, marijuana would no longer be categorized as a Schedule I drug, a classification it shares with substances like heroin and LSD. Instead, it would be considered a Schedule III substance, placing it in the same category as ketamine and certain anabolic steroids. While this reclassification would not legalize recreational marijuana use nationwide, it could lead to changes in regulatory oversight and alleviate the substantial tax burden faced by the cannabis industry.
President Trump emphasized that he had received overwhelming support for this decision, particularly from individuals advocating for the potential benefits of marijuana in alleviating pain for patients in need. Conversely, during the previous administration under Democrat Joe Biden, the Justice Department had also proposed reclassifying marijuana to a Schedule III substance.
Although not all members of his party endorsed the move, with some Republicans expressing opposition and urging the maintenance of current drug classifications, the executive order signifies a shift in federal drug policy. The DEA, which was in the process of reviewing marijuana’s classification at the beginning of Trump’s term, is now expected to expedite the reclassification process, though the exact timeline remains uncertain.
Despite the legalization of marijuana for recreational or medicinal purposes in many states, federal laws have remained stringent, potentially exposing individuals to federal prosecution. Public opinion has increasingly favored a more lenient approach to marijuana, with Gallup polling indicating a notable rise in support for legalization over the years.
In addition to reclassification, Trump’s executive order also seeks to enhance research opportunities and accessibility to CBD, a hemp-derived product that is legal but subject to debate among experts regarding its benefits. Dr. Mehmet Oz, who leads the Centres for Medicare and Medicaid Services, announced a new Medicare program that would provide older adults with access to legal hemp-derived CBD at no cost if recommended by a healthcare provider.
As part of his broader drug policy agenda, Trump has focused on combatting other substances such as fentanyl, ordering military actions against vessels believed to be trafficking drugs. He recently signed an executive order declaring fentanyl a weapon of mass destruction, underscoring his administration’s efforts to address the opioid crisis.
Despite these initiatives, Trump has not committed to decriminalizing marijuana entirely, maintaining that the issue should be primarily determined at the state level. The executive order represents a significant step towards reshaping federal drug policy and aligning it more closely with evolving attitudes and research on marijuana.
